The FDA alert on suicidality and antiepileptic drugs: Fire or false alarm?

Area of Science:

• Neurology
• Pharmacology
• Psychiatry

Background:

• The U.S. Food and Drug Administration (FDA) issued an alert regarding increased suicidality risk associated with 11 antiepileptic drugs (AEDs).
• An FDA advisory panel recommended against a black-box warning for AED labels, a decision the FDA accepted.

Purpose of the Study:

• To critically evaluate the FDA's 2008 alert on AEDs and suicidality.
• To review the literature on suicidality, depression in epilepsy, and AEDs.
• To propose recommendations for future clinical trials and patient monitoring.

Main Methods:

• Analysis of adverse event data versus systematically collected data in the FDA alert.
• Review of existing literature on suicidality, depression, and AEDs.
• Contextualization of the FDA alert within the broader understanding of epilepsy treatment.

Main Results:

• The FDA alert grouped 11 AEDs with different mechanisms and risk profiles inappropriately.
• Adverse event data used in the alert lacked systematic collection, potentially skewing results.
• The risk of uncontrolled seizures likely outweighs the observed small risk of suicidality from AEDs.

Conclusions:

• The FDA's grouping of AEDs and reliance on adverse event data were problematic.
• Routine screening for depression, anxiety, and suicidality in epilepsy patients is recommended.
• Future clinical trials should systematically assess these conditions using validated instruments to clarify the FDA's observed signal.